دورية أكاديمية
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
| العنوان: | The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. |
|---|---|
| المؤلفون: | Abraham, Jean E, Pinilla, Karen, Dayimu, Alimu, Grybowicz, Louise, Demiris, Nikolaos, Harvey, Caron, Drewett, Lynsey M, Lucey, Rebecca, Fulton, Alexander, Roberts, Anne N, Worley, Joanna R, Chhabra, Anita, Qian, Wendi, Vallier, Anne-Laure, Hardy, Richard M, Chan, Steve, Hickish, Tamas, Tripathi, Devashish, Venkitaraman, Ramachandran, Persic, Mojca, Aslam, Shahzeena, Glassman, Daniel, Raj, Sanjay, Borley, Annabel, Braybrooke, Jeremy P, Sutherland, Stephanie, Staples, Emma, Scott, Lucy C, Davies, Mark, Palmer, Cheryl A, Moody, Margaret, Churn, Mark J, Newby, Jacqueline C, Mukesh, Mukesh B, Chakrabarti, Amitabha, Roylance, Rebecca R, Schouten, Philip C, Levitt, Nicola C, McAdam, Karen, Armstrong, Anne C, Copson, Ellen R, McMurtry, Emma, Tischkowitz, Marc, Provenzano, Elena, Earl, Helena M |
| بيانات النشر: | Springer Science and Business Media LLC //dx.doi.org/10.1038/s41586-024-07384-2 Nature |
| سنة النشر: | 2024 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Adult, Aged, Female, Humans, Middle Aged, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Genes, BRCA1, BRCA2, Neoadjuvant Therapy, Paclitaxel, Pathologic Complete Response, Phthalazines, Piperazines, Progression-Free Survival, Prospective Studies, Survival Analysis, Time Factors, Triple Negative Breast Neoplasms, Adolescent, Young Adult |
| الوصف: | Acknowledgements: We thank the patients, and the families and friends who supported them, for participating in this trial; our ethics committee, our independent data and safety monitoring committee and the trial management group for their advisory roles; the PARTNER trial consortium members, past and present (Supplementary Information); and I. Cizaite for preparing and proofreading the manuscript. This trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and financed by a project grant from AstraZeneca, who also supplied olaparib. Cancer Research UK provided peer review and endorsement for the study and financed the sample collections for the translational studies, which will be reported separately. We also acknowledge the National Institute for Health and Care Research Cambridge Biomedical Research Centre and the Cancer Research UK Cambridge Centre for their financial support for staff and infrastructure costs. The funders had no role in data collection or analysis. Once the trial group had interpreted the data, the results were then shared with the AstraZeneca scientists. In addition, we thank the Cancer Molecular Diagnostics Laboratory and The Precision Breast Cancer Institute Team for their support for sample collection; Cambridge Tissue Bank (NIHR203312) for sample assessment and diagnostics; Cambridge Clinical Trials Centre – Cancer Theme for their core staff support; the clinical trials support staff at all participating sites; and Addenbrookes Charitable Trust for financing the post of the chief investigator (2015–2018). We acknowledge Cancer Research UK (CRUKE/14/048) and AstraZeneca (1994-A093777). ; PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/zip; text/xml; application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/369017Test |
| الإتاحة: | https://www.repository.cam.ac.uk/handle/1810/369017Test |
| رقم الانضمام: | edsbas.AE0EA7A1 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |